TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Investing.com - Morgan Stanley initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with an Overweight rating and a $70.00 price target, highlighting the company’s protein degradation and ...

Kymera Therapeutics announces $250.8 million public offering of common stock and pre-funded warrants to advance its biopharmaceutical programs.

Investing.com - Brookline Capital Markets lowered its price target on Kymera Therapeutics (NASDAQ: KYMR) to $70.00 from $97.00 on Wednesday, while maintaining a Buy rating on the stock. The ...

The latest international Kymera Therapeutics Inc news and views from Reuters - one of the world's largest news agencies ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the ...

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.